Table 4.
Parameters | β | SE | Wald χ2 | P | HR | 95%CI |
---|---|---|---|---|---|---|
Age | .107 | .072 | 2.225 | .135 | 1.114 | 0.979 ~ 1.265 |
Sex (female vs male) | .233 | .124 | 3.531 | .061 | 1.266 | 0.987 ~ 1.605 |
BMI | .076 | .101 | 0.547 | .460 | 1.087 | 0.876 ~ 1.317 |
LncRNA ANRIL levels | .180 | .066 | 7.747 | .004 | 1.197 | 1.054 ~ 1.357 |
Medication (warfarin vs dabigatran and rivaroxaban) | .298 | .316 | 1.537 | .170 | 1.176 | 0.917 ~ 1.742 |
NIHSS score at the occurrence of ischemic stroke | .105 | .009 | 136.111 | .001 | 1.111 | 1.091 ~ 1.130 |
Infarct volume | .211 | .102 | 4.464 | .035 | 1.232 | 1.016 ~ 1.510 |
Hypertension (yes vs no) | .294 | .173 | 2.888 | .089 | 1.342 | 0.956 ~ 1.883 |
Diabetes mellitus (yes vs no) | .783 | .473 | 2.742 | .098 | 2.188 | 0.866 ~ 5.531 |
Smoking history (yes vs no) | .387 | .026 | 20.520 | <.001 | 1.472 | 1.251 ~ 1.738 |
Drinking history (yes vs no) | .632 | .501 | 1.591 | .207 | 1.881 | 0.705 ~ 5.032 |
Family history of ischemic stroke (yes vs no) | .725 | .449 | 2.607 | .106 | 2.065 | 0.856 ~ 4.978 |
TC | .377 | .563 | 0.448 | .503 | 1.458 | 0.484 ~ 4.395 |
HDL‐C | .286 | .300 | 0.909 | .340 | 1.331 | 0.739 ~ 2.396 |
LDL‐C | .198 | .473 | 0.175 | .676 | 1.219 | 0.482 ~ 3.080 |
Lp (a) | .273 | .338 | 0.652 | .419 | 1.314 | 0.677 ~ 2.548 |
PCT | .542 | .302 | 3.221 | .073 | 1.719 | 0.951 ~ 3.108 |
Fibrinogen | .501 | .328 | 2.333 | .127 | 1.650 | 0.868 ~ 3.139 |
D‐dimer | .473 | .440 | 1.156 | .282 | 1.605 | 0.677 ~ 3.802 |
Hs‐CRP | .732 | .801 | 0.835 | .361 | 2.079 | 0.433 ~ 9.994 |
Abbreviations: BMI, body mass index; CI, confidence interval; HDL‐C, high‐density lipoprotein‐cholesterol; HR, hazard ratio; Hs‐CRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein‐cholesterol; Lp (a), lipoprotein (a); mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PCT, procalcitonin; SE, standard error; TC, total cholesterol; β, regression coefficients.